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Abstract
This thesis outlines the theoretical basis of the hypothesis that women who die of
early breast cancer experience a burst of mutations in any number of oncogenes or tumor
suppressor genes during the development of the mammary gland in puberty. The basis of
this hypothesis is derived from previous experiments in which the mammary epithelium of
untreated sexually immature 50 day old female Fischer 344 rats contained clusters of c-H-
ras codon 12 G->A mutants. The average size of these mutant clusters and their
distribution within the glands indicated that they arose earlier in the pubertal development
of the gland. We have examined the birth year cohort age-specific breast cancer mortality
curves for both European American and African American females born in the years 1867,
1877, 1887, 1897, 1907, 1917, 1927 and 1937. We have postulated that the overall shape
of the curve which may be separated into two distinct populations indicates a possible
epidemiological basis of our hypothesis.
We have laid out the development of the mammary gland during each of its
hormonal stages, i.e. puberty, pregnancy and menopause and have estimated within an
order of magnitude the number of epithelial cells at risk during each of these stages. We
have also modeled the epithelial cell kinetics during the development of the gland during
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puberty and have outlined the possible scenarios for the appearance of spontaneous
mutant cell clusters during this period.
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1. INTRODUCTION
1.1 The Mutational Basis of Cancer
The field of genetic toxicology has had at its foundation the premise that humans
are exposed to exogenous chemicals which induce mutations in cellular genes, which
subsequently lead to the development of cancer in a susceptible organ. Somatic mutations
have been found in at least two classes of genes (proto-oncogenes and tumor suppressor
genes) in both human and experimental animal tumors. The spectrum of mutations found
in these tumors range from chromosomal rearrangements such as translocations or gene
amplification to large scales insertions or deletions to point mutations. For example, the
activation of the K-ras oncogene and the inactivation of at least 3 tumor suppressor genes,
including the adenomatous polyposis coli (APC) gene have been found to occur in human
colon tumors (Fearon et al., 1990). The normal cellular counterparts of oncogenes, termed
"proto-oncogenes" function in controlling cell growth and differentiation, while normal
tumor suppressor genes act as negative regulators of cell division.
Molecular characterization of spontaneous and chemical induced tumors generated
in several rodent model systems revealed the presence of activated ras oncogenes, which
were first discovered in avian and murine oncoviruses. Activated ras oncogenes have also
been found in quite high percentages in colon carcinomas, pancreatic carcinomas, lung
adenocarcinomas, cholangiocarcinomas, certain types of thyroid tumors, endometrial
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adenocarcinomas, mucinous carcinomas of the ovary, squamous cell carcinomas and to a
much lesser extent in several other types of human tumors (Anderson et al., 1992). It was
difficult to define the precise role of oncogene activation in the initiation and development
of human cancers. The availability of animal model systems, in particular, rodent model
systems, in which oncogenes could be reproducibly activated by chemical treatment made
the goal of defining the role of the oncogenes in the multistep process of carcinogenesis
more realistic. The reproducible activation of the ras oncogene in chemical induced rodent
tumors made it possible to correlate the activating mutations with the pre-mutagenic
adducts which were supposedly formed directly by the carcinogen. In particular, rodent
mammary models proved useful for studying the mechanisms of human mammary
carcinogenesis.
1.2 Mammary Carcinogenesis
1.2. 1Breast CancerMortality Data
The current estimate of every 1 in 8 American women developing breast cancer
during the course of a lifetime has caused an increase in research activity in this field. We
have obtained the breast cancer mortality data (Vital Statistics of the United States) and
have separated it according to birth years and plotted it accordingly. The composite birth
year cohort age-specific mortality breast cancer curves for European American females and
non-European American females born in the years 1867, 1877, 1887, 1897, 1907, 1917,
1927 and 1937 are shown in Figures 1 and 2 respectively.
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Figure 1 - Birth year cohort age-specific breast cancer mortality curve for European
American Females
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Figure 2 - Birth year cohort age-specific breast cancer mortality curve for Non-European
American Females
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Examination and analysis of the mortality curves reveals a reproducibly distinct
inflection in the curves around the ages of 55-65. There is a peak in the curve somewhere
around age 55, followed by a relatively flat 5 year period. After this point, the curves
begin to rise again in an approximately linear fashion. This inflection suggests to us that
there might be two separate populations of women who die of breast cancer. We may
separate the overall curve into two separate populations by more or less symmetrically
extrapolating the first part of the curve to yield "Population 1". The second population
curve may be obtained by subtracting the extrapolated values from "Population 1" from
the overall values of the combined curve. We may then postulate that the breast cancers in
both populations occur by distinct mechanisms, the kinetics of which may be considered
separately. It must however be noted that if the rates of dying of breast cancer for the
women in "Population 2" begin to increase, it is possible that we may no longer observe
the inflection in the overall mortality curve. It is interesting to note that at values of "t"
corresponding to "Population 1", the slope of the curve of "P(t)" vs "t" does not increase
with birth year. In contrast, the slope of the curve of "P(t)" vs ""t" increases with
advancing birth year for "Population 2".
Two clearly distinct populations are also observed in the birth year cohort age-
specific mortality curves for testicular cancer and Hodgkin's lymphoma. Figures 3, 4 and
5 depict the birth year cohort age-specific mortality curves for European American Female
Hodgkin's lymphoma, European American Male Hodgkin's lymphoma and European
American Male Testicular cancer respectively. Examination of Figures 3 and 4 show that
the first population begins dying off around age 15, peaks at age 35 and then falls. The
second population then begins to rise around age 50. In the case of testicular cancer, an
examination of Figure 5 reveals a first population reminiscent of that in Hodgkin's
lymphoma. Similarly, the curve of the first population begins to rise around age 15, peaks
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between ages 30 to 35 and then begins to fall. The second population in testicular cancer
however begins to rise around ages 60 to 65, in contrast to age 50 in Hodgkin's lymphoma.
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Figure 3 - Birth year cohort age-specific Hodgkin's lymphoma mortality curve for European
American females
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Figure 4 - Birth year cohort age-specific Hodgkin's lymphoma mortality curve for European
American males
-19-
Testicular Cancer (European
20 40 60 80 100 120
Age
Figure 5 - Birth year cohort age-specific testicular cancer mortality
American males
curve for European
1.3 The Alternative Hypothesis of Rodent Mammary Carcinogenesis
The reproducible induction of mammary carcinomas after treating sexually
immature female rats with the methylating agent, N-nitroso-methylurea (NMU) provided
a useful model for the study of human mammary carcinogenesis. Specific G->A mutations
were consistently found in codon 12 of the c-H-ras gene in these tumors. The collective
hypothesis that arose from these experiments (see Appendix for detailed descriptions) is
that chemical carcinogens act as initiators in the multi-stage theory of carcinogenesis by
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directly inducing the oncogenic mutations which are later found in tumors. It was
presumed that as tumors are monoclonal, the nature of the predominant genetic changes in
the tumors is indicative of both the timing of the event and the chemical responsible for the
changes.
For many years, the idea that NMU induced the specific mutation in the mammary
epithelial cells which later underwent clonal expansion and developed into mammary
tumors dominated the field of oncogenesis. However, there is an alternative hypothesis
which was never seriously investigated. It is quite possible that the chemicals are not
directly inducing the mutations which are observed in the resulting tumors, but are simply
selecting the pre-existing mutant cells. It may be that the mutations arose prior to
treatment with the chemical, perhaps during the window of time between the onset of
puberty and treatment with the chemical. In the case of rats, treatment with the chemicals
usually takes place at about 50-55 days of age and the onset of puberty occurs around 35
days of age (Dr. Rita Cha, Ph.D. Thesis, MIT 1992). Therefore, there is a window of
approximately 15-20 days in which the mammary gland is undergoing development via
branching of the ducts and proliferation of the mammary epithelial cells lining the ducts.
In this stage of rapid cell proliferation, it is possible that spontaneous mutations, in this
case in the c-H-ras gene may occur. Treatment with NMU may have some independent
effect on the c-H-ras mutant cells, possible selecting them and promoting their
proliferation into mammary tumors.
Despite the fact that the resulting mammary tumors may contain predominantly
codon 12 mutations in the c-H-ras gene, this may not mean that these are the predominant
mutations induced by NMU, (assuming that NMU induced the mutations). A tumor is a
clonal population which was selected in vivo and for this reason, we may not assume that
the predominant mutation is the one induced by the chemical. The only information that
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may be garnered is that the cells with the predominant mutation have a selective growth
advantage and that these mutant cells were present earlier in the development of the
mammary tumor. It is possible that the chemical induces other mutations which do not
have a selective growth advantage and may not be detected because the mutant frequency
is below the level of detection of the specific assay.
1.4 Testing the Alternative Hypothesis
Cha et al., (1994) were the first to directly test this alternative hypothesis, by
trying to prove that the oncogenic mutations which are detected in chemical-induced
rodent tumors are directly induced by the chemical carcinogens themselves. They set out
to determine if a carcinogenic dose (30 mg/kg) of NMU administered to female Fischer 344
rats induced mutations in the the c-H-ras oncogene of mammary epithelial cells or if the
mutations were pre-existing.
Using the mismatch amplification mutation assay (MAMA) which was key to the
testing of the hypothesis and had a demonstrated sensitivity of 10-5 (Cha et al., 1992),
they determined that the G->A transition mutation at codon 12 of the c-H-ras gene existed
in the mammary epithelium of these rats prior to treatment with NMU (Cha et al., 1994).
They hypothesized that NMU acted in a manner independent of inducing the codon 12
mutations and was perhaps selecting for the mammary epithelial cells bearing the
mutations, inducing them to expand and develop into a mammary tumor. The evidence for
this conclusion is based on the fact that (i) 70% of untreated animals contained detectable
levels of c-H-ras mutants (an average of about 128 mutants per animal), (ii) the mutants
were clustered as sectors within the mammary gland and (iii) that treatment with the
carcinogenic dose of NMU did not result in a significant increase in the number of mutants,
the fraction of organ sectors with mutant cells or the fraction of animals containing
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detectable levels of c-H-ras mutants. Table 1 shows the distribution of c-H-ras mutant
cells in sectored mammary tissue of 50 day old untreated Fischer 344 rats (taken from Cha
et al., 1994). By determining the average number of c-H-ras mutants per sector and their
distribution in the rat mammary gland, Dr. Cha and her colleagues were able to conclude
that there was a "burst" of mutations and to pinpoint the "timing" of the burst close to
the first estrus'. The clustering of the c-H-ras mutants as sectors in the gland is consistent
with their origin as descendants of single cells which mutated early in the development of
the gland. Otherwise, if the mutants arose independently or at a time closer to the
attainment of maximum cell number of the organ, they would be randomly and evenly
distributed throughout the organ. This is based on the logic that the induced mutants
would not have had sufficient time/doublings to clonally expand and develop into colonies.
It must be remembered however, that the limit of sensitivity of the MAMA assay does
not allow us to distinguish between truly independent mutants and colonies which have
not yet attained sufficient mutant cells (mutant fraction required >= 10-5), which would
allow them to be scored as positive sectors.
tDr. Cha determined the timing of the burst using the following method (Dr. R. Cha, doctoral thesis,
1992).
Sectors that she analyzed from 50 day old rats contained on average 128 (27) mutant colonies. Assuming
that each sector arose from a single cell, she determined that the single mutation in these sectors arose 8 cell
divisions prior to the time of observation. Using the observation that the cell division cycle in young virgin
rats varies between 10 and 28 hours (Russo and Russo, 1988), she was able to calculate that the early event
occurred around 40 days of age.
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Tablel. Distribution of H-ras mutant cells in sectored mammary tissue of 50 day old
untreated Fischer 344 rats (from Cha et al., 1994)
ANIMAL SECTOR MUTANT/SECTOR MUTANT
FRACTION
50-1 D 150 2.1x10-5
50-2 E 100 1.4x10 -5
50-4 A 110 1.6x10 -5
D 50 0.7x10 -5
E 80 1.2x10-5
50-5 B 200 2.8x10-5
C 150 2.1x10 -5
50-6 C 120 1.7x10-5
Average # of mutants 322
2 This includes both positive and negative mammary tissue sectors
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2. 1 Hypothesis
The results of Cha et al. (1994) have altered our perspective on the mechanism of
rat mammary carcinogenesis. The mutations which are found in the rat mammary tumors,
if indeed spontaneous in origin, will force us to consider the contributions to the overall
role of carcinogenesis of endogenous agents in human mammary carcinogenesis. Their
observations prompted us to think that perhaps a similar phenomenon (a burst of
spontaneous mutations during puberty) might be occurring in humans. We then decided to
determine if there was any theoretical evidence that would support our notion of a
pubertal burst occurring during the growth of the mammary gland in puberty. Using the
shape of mortality curves for a number of different cancers as a reference, we may predict
the shapes of the breast cancer mortality curves, if indeed a pubertal burst did occur. As
shown in Figure 6, there would be an early population which would begin dying off
beginning somewhere around age 25. The curve would then peak and begin to fall until age
40-45. The predominant pattern which is found in tumors in which there is no expected
pubertal burst would be an approximately linear increase in the curve beginning around age
55-60, which is also shown in Figure 6. The composite of both of these curves is shown
in Figure 7, and is remarkably reminiscent of the breast cancer mortality curves (birth year
cohort specific data for the years 1867-1937) shown in Figures 1 and 2.
HYPOTHESIS
The basis of this thesis was to determine if women who die of early breast cancer
experience a burst of mutations during the growth of the mammary gland during puberty in
any number of oncogenes or tumor suppressor genes.
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2.2 The Human Mammary Gland
2.2.1 General Structure of Mammary Gland
The structure of the mammary gland varies with the hormonal status of the
individual. The human mammary gland may be divided into three structural
compartments:
* the glandular tissue, i.e. epithelial cells of the compound tubulo-alveolar type, which is
further divided into lobes
* connective tissue which surrounds the glandular tissue and separates lobes from each
other
* interlobular adipose tissue.
The glandular component is composed of a tree-like network of branching ducts
and terminal secretory lobules, which becomes increasingly ramified as it extends away
from the nipple in both the radial and longitudinal directions. The gland consists of 15-25
lobes, each of which converges to a lactiferous duct which then opens up into the
lactiferous sinus at the apex of the nipple. The lactiferous ducts lead into the terminal
interlobular ducts (TID), each of which further divides into several intralobular ducts.
Gray's Anatomy (38th edition) cautions that even though the lobes of the mammary gland
are depicted as discrete anatomical regions in the gland, they typically grow into each other
at the edges and do not look like discrete structural entities during surgery. Lobules are the
terminal secretory portion of the branching structure and their structures are dependent on
the hormonal status of the gland. In the mature breast (specialized for milk production and
secretion), each lobule consists of several blind ending extensions, termed as alveolar buds,
ductules or alveoli (acini) depending on their stage of development. Each of these branches
converge and form an alveolar duct through which the milk is secreted.
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The connective tissue stroma of the mammary gland loosely encapsulates and
surrounds the lobules, thus accomodating easy, rapid expansion of the glandular portion of
the organ both during puberty and pregnancy. Adipose tissue occurs between the lobules
in a lobe and the quantity is also dependent both on the individual and the hormonal status
of the individual.
The ducts are lined by columnar epithelium for most of their length. Larger ducts
are typically lined by two layers of cells, while the smaller ones are lined by a single layer
of epithelium (luminal epithelium). The bases of the luminal epithelial cells are in close
contact with numerous myoepithelial (basal) cells which invaginate their bases and form a
separate layer surrounding the ducts and alveoli. The lactiferous ducts are lined with
stratified cuboidal epithelium and close to their openings at the apex of the nipple, the
stratified cuboidal epithelium is replaced by keratinized stratified squamous epithelium.
Figure 8 depicts the ultrastructure of the resting mammary gland (Krstic, 1991).
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Figure 8 - Ultrastructure of the resting human mammary gland (Krstic, 1991)
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2.2.2Pre-Natal Development of the Human Mammary Gland
The first evidence of the mammary gland appears as the milk streak during the 4th
week of gestation, when the fetus is approximately 2.5 mm long. The milk streak then
becomes the mammary ridge or the milk line during the 5th week. According to the
qualitative ultrastructural observations of Dabelow (1957) described by Russo and Russo,
the process of gland development in the fetus may be characterized into 9 different stages.
The first stage is the thickening of the mammary ridge stage which is termed the "milk hill"
stage in the 6th week, followed by the "mammary disc" stage when parenchymal cells
start to invade the underlying stroma. The "mammary disc" stage then progresses to the
globular stage between the 7th and 8th week. Subsequent to this is the cone stage which
occurs at the 9th week and is characterized by further inward growth of the mammary
parenchyma. Epithelial buds sprout from the invading parenchyma and these buds
become lobular in shape between the 12th and 13th week, with notching at the epithelial-
stromal border, otherwise known as "indentation". The next stage is called the
"branching" stage and is marked by the appearance of 15-25 epithelial strips or solid cords
in the 15 week old fetus. The canalization stage occurs next between 20 and 32 weeks of
gestation and the solid cords become "canalized" by desquamation and lysis of the central
epithelial cells. The final stage is the end-vesicle stage in which the end vesicles contain
colostrum and have a monolayer of epithelial cells. Lobules have thus far never been
observed in the fetal mammary gland. Their formation has been associated only with the
onset of puberty. The male and female mammary glands are structurally similar at birth,
with the exception that the male mammary gland never undergoes hormone-mediated
development.
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2.2.3 Development of the Human Mammary Gland During Puberty
Development of the mammary gland is initiated during puberty and varies from
woman to woman. Mammary gland development may be characterized by determining the
mammary gland area, volume, degree of branching of the ductal network, the degree of
structures, such as lobules whose appearance shows the level of differentiation of the
gland, or a combination of each of these variables. At the onset of puberty, somewhere
between ages 11 and 13, an increase in the secretion of estrogen and progesterone (see
Figure 9 for details on the age correlated systemic levels of the hormones) drives the
proliferation and branching of the ductal network and an accompanying increase in the
density of the surrounding stroma, characterized by an increase in deposition of
collagenous connective tissue and adipose tissue. This accounts primarily for the increase
in size of the mammary gland during puberty. The ducts grow and divide in both a
dichotomous (repeated bifurcation) manner and a sympodial manner (formation of an
apparent main axis form successive secondary axes) on a dichotomous basis. The ducts
lengthen, divide and form club-shaped terminal end buds, which later become small
ductules or alveolar buds. The alveolar buds then become acini or alveoli. The
ductules/alveolar buds are morphologically more developed than the terminal end buds but
less developed than the acini (alveoli). According to Russo and Russo, the alveolar buds
cluster around a terminal duct forming a type 1 lobule. These terminal ducts or alveolar
buds are lined by two layers of epithelial cells, whereas the terminal end buds are lined by
up to four layers of epithelium. The acini are the secretory unit of the mammary gland.
Lobule formation occurs within 1-2 years after the first menarche.
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2.2.4 The Mammary Gland During Pregnancy
The breast achieves its maximal state of development during pregnancy. There are
two distinct stages; the first is characterized by the proliferation of the distal portions of
the ductal network (otherwise referred to as lobule formation), resulting in the
transformation of ductules or alveolar buds to acini (alveoli). Rapid proliferation and
morphological development of the functional secretory units occurs during the first three
months of pregnancy. The epithelial cells in the acini of the newly formed lobules increase
greatly in number as they are actively undergoing cell division and they also increase in
size due to cytoplasmic enlargement. It was not possible to garner any information in the
literature about whether there is a distinct "stem cell" population which is responsible for
most of the cell division and increase in epithelial cell population or if all the cells in the
ductal network are capable of undergoing cell division. I would postulate that it would be
more efficient for the gland to have a reserved "stem cell" population which would remain
at the distal portions of the ductal network. As the network grows radially and
orthogonally away from the apex of the nipple, the cells in the distal portion of the ducts
would automatically give rise to the components of the new lobules. We must also note
that as the glandular portion of the breast increases, the stromal component actually
decreases to accomodate the expanding glandular compartment.
During the middle of pregnancy, the lobules are further enlarged and increased in
number. The lobules at this stage still contain a combination of terminal ducts and acini.
Certainly, by the end of the first half of pregnancy, the groundwork for the structure of
the expanded ductal network is already established. The second half of pregnancy is
characterized mostly by differentiation into the milk secreting acini, which are the fully
differentiated structures. These acini are not susceptible to neoplastic transformation and
hence would theoretically reduce the number of cells at risk. This structure is maintained
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throughout lactation. However, the post-lactational stages of the mammary gland are
marked by a regression of the alveolar/ductal system, an increase in apoptosis of the
epithelial cell population and a decrease in their cell size.
2.2.5 The Mammary Gland During Menopause
The decrease in the secretion of ovarian hormones, beginning around age 45 causes
a regression in the glandular structure of the mammary gland. The main ducts and their
branches remain, while there is shrinkage and collapse of the lobules. There is an increase
in the fat and connective tissue content of the gland.
2.3 The Hormonal Status of the Pre-Pubertal and Pubertal Mammary Gland
Female puberty is characterized by a number of endocrine changes. Some of these
changes are actually initiated several years before the first menarche (average age of 12
[Gray's Anatomy, 38th Edition]). The hormonal status of the pre-pubertal and the
pubertal mammary gland is an important factor in our hypothesis. The link between the
physiology and the endocrinology of the gland during the different stages of its
development and the molecular changes underlying the hypothesized mutational burst is
unknown. Such vital information is unfortunately unavailable in the existing literature.
Vihko and Apter gathered data on some 200 health girls aged 7 -18 years and were able to
come up with average systemic concentrations of several hormones, including estradiol and
progesterone. We focused on the concentrations of estraogen/estradiol and progesterone as
these are the strategic hormones driving the maturation and development of the mammary
gland during puberty. Figure 9 represent the graphs of the concentrations of estradiol and
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progesterone respectively which have been adapted from the data presented by Vihko and
Apter.
Examination of Figure 9 shows that the concentration of estradiol increases two
fold between the ages of 7 and 9 (0.025 nM - 0.05 nM). Over the course of the following
four years (ages 9-13), the concentration of estradiol increases five fold, leveling off at
0.2375 nM for about two years until age 15. An additional slight increase occurs again
from age 15 until age 17 and finally flattens at 0.275 nM. The overall concentration of
estradiol increases 11 fold in the period of approximately 11 years. The concentration of
progesterone also changes significantly throughout the pre-pubertal and pubertal years.
The increase in concentration is however more gradual than that of estradiol and increases
overall by approximately 2.3 fold (0.3 nM - 0.7 nM) over the span of 11 years. The
progesterone concentration increases 1.3 fold during the first 4 years (ages 7-11), 1.25 fold
between 11 and 12, holding steady until age 14 and finally increasing 1.4 fold between ages
14 and 18. Data on the post-pubertal concentrations of these key enzymes have not been
found in the literature.
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Concentration of estradiol and progesterone
in 7-18 year old females
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Figure 9 - Concentration of Estradiol and progesterone in 7-18 year old females
2.4 Estimated Number of cells as a Function of the Hormonal Status
In an effort to obtain an order of magnitude estimate of the number of epithelial
cells at risk of transformation in the human mammary gland as a function of the hormonal
status of the gland, we have gathered data from several sources and made several
assumptions. Russo and Russo determined the level of differentiation of lobules in the
breast tissue of 22 adult women, ranging in age from puberty to 63 years of age who were
undergoing reduction mammoplasties. Morphologically, lobules can be characterized as
type 1, type 2, type 3 and type 4. They found that lobules of type 1 were found mainly
in pubertal and young nulliparous pubertal women, while type 2 and type 3 lobules were
found in parous, non-pregnant women and type 4 lobules were found primarily in
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pregnant women. They have also measured parameters such as the number of cells per
alveolar bud/ductule/acinus depending on the lobule type and the number of alveolar
buds/acini/ductules per lobule. A summary of this data is shown in Table 2. The
hierarchy of structures in the mammary gland is as follows: epithelial cell ->
ductule/alveolar bud/acinus ->lobule -> lobe. Since the hormonal status of the gland has
been determined as a function of the type of lobules found in breast tissue, we are
assuming that the parameters for the different lobule types may be used to represent the
different hormonal stages in the mammary gland. Therefore, parameters for lobules type 1
may be used to estimate the number of cells at risk for young post-pubertal women,
lobules type 2 and 3 for parous post-pubertal non-pregnant and nulliparous young women
and lobules type 4 for pregnant women.
Number /lobule3
# cells/cross-section 4
Cross-sectional
area/lobule (mm2)
Lobule Type 1
11.20
32.43
0.048
Lobule Type 2
47.0
13.14
0.060
Lobule Type 3
81.0
11.0
0.129
Lobule Type 4
180.0
10.0
0.250
.Table 2 Number of epithelial cells per cross section of alveolar bud/ductule/acinus,
number of alveolar buds/ductules/acini per lobule and cross-sectional area
per lobule (mm2)
" # of alveolar buds/ductules or acini per lobule
4 # of epithelial cells per cross-section of alveolar bud/ductule or acini
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The number of epithelial cells at risk in each lobe may be determined by
multiplying the number of cells per cross-section of either alveolar bud/ductule/acinus by
the number of lobules in each lobe. We may then obtain the number of epithelial cells per
breast as we know that there are between 15-25 lobes per breast depending on the
individual. For the purposes of our calculations, we have chosen to use an average of 20
lobes per breast. Since a measurement of the number of lobules per lobe is not available,
we have estimated the value of this parameter for lobules types 1 through 4 using the
following assumptions. We know that the mass of each breast in post-pubertal women is
between 150-200 g and increases to about 500 g during pregnancy (Gray's Anatomy, 38th
edition). Based on this, we have estimated the mass of each breast in late puberty females
to be about 100 g. Therefore, using the density of body fat (0.78 mg/mm3) and the relative
parenchyma-stroma ratio measurements made using whole mount studies of 14 human
breasts of pubertal, post-pubertal and pregnant women by Russo and Russo, we are able
to determine the total volume of the mammary gland occupied by the lobules. Russo and
Russo have found that 10% of the mammary gland in late pubertal females is composed of
parenchyma, and this value increases to 30% in post-pubertal and young nulliparous
women. During pregnancy, this ratio changes significantly and during the first half of
pregnancy, 55% of the gland is composed of parenchyma while it increases to 73% during
the second half of pregnancy. The volume of each lobule may be estimated as we have the
cross-sectional area of lobules types 1-4, and we are assuming that the lobule may be
modeled as a sphere. Therefore, the number of lobules per lobe may be obtained by
dividing the total volume of each breast occupied by lobules by the volume of each lobule.
The number of cells per lobe may then be obtained by multiplying the number of
lobules/lobe by the number of cells/lobule (Table 2). Multiplying this parameter by 20
(average number of lobes/breast) gives an estimate of the number of epithelial cells at risk
in each breast. Table 3 shows the values of all the estimates of the parameters which have
been obtained using the above assumptions. It must also be noted that the number of
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epithelial cells at risk during the second half of pregnancy is overestimated as a large
number of the epithelial cells in the first half of pregnancy have become fully differentiated
milk producing acini and are no longer susceptible to neoplastic transformation.
Total volume
of breast
occupied by
lobules
radius of lobule
Volume/lobule
#1obules/lobe
#cells/lobe
#cells/breast
Type 1
7.8 x 10'
mm 3
0.124
mm
7.9x1 0 3
mm 3
9.8x105
1.1x10 7
2.2x10 8
Type 2
3.51-
4.68x104
mm
3
0.138 mm
1.1xl0-
mm
3
3.19-
4.25x106
1.49-
1.99x108
2.98-
3.98x10 9
Type 3
3.51-4.68x104
mm 3
0.203 mm
3.5x10- 2 mm3
1.0-1.33x10 6
8.1xl0 7 -1.08x10 8
1.62-2.16x10 9
Type 4 - 1st half
pregnancy
2.145 xl01
mm
3
0.282 mm
9.39x10 2 mm3
2.28x1 06
4.1x10'
8.2x10 9
Type 4 - 2nd half of
pregnancy
2.85 xl0 mm
0.282 mm
9.39x10 - mm3
3.03x10 6
5.45x108
1.09x10 lo
Table 3 - Values of parameters obtained necessary for the order of magnitude estimate of
the number of epithelial cells at risk in the breast
2.5 Potential Relationship Between Breast Cancer Risk Factors and Tissue
Kinetics
Early age at menarche (age 11 and before), late menopause (> 55 years of age), and
age at first full term pregnancy (FFTP) have been identified as "risk factors" for the
development of breast cancer [Moolgavkar et al., (1980), Pike et al., (1981), MacMahon et
al., (1970), Trichopoulos et al., (1972)]. We can try to relate these risk factors with the
events which are taking place at the cellular level as the organ proceeds through its
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hormone-mediated stages of development. Pike et al., (1981) found that the relative risk
for developing breast cancer in women aged 32 or younger is twice as high for those who
experienced menarche at 11 versus those who experienced menarche at 13 or older.
MacMahon et al., (1970) showed that nulliparous women in an age-controlled study had a
relative risk that was twice the value for women who had a FFTP before the age of 20. If
the FFTP was between the ages of 20 to 24, 25 to 29 or 30-35, the relative risk increased
by 20%, 56% and 88% respectively. It appears that the key factor is the age at FFTP as
the relative risk does not decrease significantly with subsequent full term births (FTB),
controlling for age at FFTB. Trichopoulos et al., (1972) have also estimated that women
whose natural menopause occurred before age 45 had about half the breast cancer risk as
the women whose natural menopause occurred after age 55. Based on our hypothesis,
these kinetics probably affect "Population 2".
For the sake of speculating on the possible tissue kinetics which might be
underlying the epidemiological observations, we shall think of the mammary gland as a
homogeneous population of cells which are susceptible to transformation. As mentioned
previously, the cells in the mammary gland which are susceptible to the development of
carcinomas are the ductal epithelial cells. We are making the simple assumption that breast
cancer risk is determined solely by the number of susceptible epithelial cells and
topographic factors such as the positions of these epithelial cells in the architecture of the
gland do not have any significant influence on the overall risk. We are also assuming that
the two main determinants for decreasing the size of this population are death and
differentiation.
The status of the population of epithelial cells can be characterized at each of the
hormonally distinct stages in a woman's life - puberty, pregnancy and menopause.
Epithelial cell proliferation is stimulated at the onset of puberty by increased levels of
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estrogen. The mammary gland is continuously in a state of development and the epithelial
cells undergo a limited amount of hormonally-induced proliferation during each menstrual
cycle. During the first half of pregnancy, the maturation of the gland continues and there
is much ductal branching and epithelial cell division. However, during the second half of
pregnancy, much of the epithelial cell population undergoes differentiation and becomes
specialized for the task of milk production. Regression in the levels of the hormones
which maintain the breast epithelium at the onset of menopause causes the involution of
the breast. The size of the population of susceptible cells is significantly reduced as a
result of either an increase in the death rate of the cell population, an increase in the rate of
differentiation or a decrease in the growth rate or a combination of all three factors
(Moolgavkar et al., 1980).
An early age at menarche induces early proliferation of the breast epithelium and
consequently leads to an increase in the number of susceptible epithelial cells earlier in life.
This increases the length of time for which they can acquire the rate limiting mutations in
order to acquire the selective growth phenotype. Similarly, a late menopause also increases
the length of time the epithelium is susceptible to incurring the rate limiting mutations. At
the onset of menopause (45-55), one would expect a population of cells which have
already acquired one of the two rate limiting mutations would exist. This would imply
that the longer this population of cells stays around, the more likely it would be that they
would acquire the second rate limiting mutation, thus setting the stages for the
development of a clinically detectable tumor. The protective effect of a full term
pregnancy probably arises from the fact that in the second half of pregnancy, the
significant fraction of the cells which arose from a rapid rate of cell turnover during the
first half of the pregnancy are removed by differentiation. This translates into a decrease
in the value of N and hence, a decrease in the value of the slope. Moolgavkar et al., (1980)
also caution us that a FTP not only decreases the population of cells which have not
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acquired any of the rate limiting mutations, but it also decreases the population of cells
which have acquired one of the two mutations. Phenotypically, these two populations
should be identical and there should be no selection for one population over the other in
the process of differentiation. Therefore, the earlier the FFTP occurs, the faster the
number of susceptible cells is decreased and the smaller the population of cells available
for acquiring the rate limiting mutations. This smaller number of cells effectively decreases
the probability of mutation induction (assuming that N is decreased by at least one order
of magnitude).
2.6 Modeling the Cell Kinetics During Development of the Mammary Gland
The kinetics of epithelial cell growth in the developing human breast is crucial to
the prediction of the expected number of mutant clusters and the average size of the
clusters. Let us consider a developing mammary gland and assume continuous growth in
time. We assume that the human mammary gland begins with 105 epithelial cells at the
onset of puberty at age 11, and most of the cell growth is complete by age 16, at which
time the mature breast contains approximately 7.5x10 8 cells5 . Therefore, the mammary
gland undergoes a 104 fold expansion in the space of about 5 years.
During the critical growth phase, the mammary gland will exhibit growth such that
the rate of growth of cells is proportional to the number of cells in the organ. In other
words, the growth of the gland is exponential and may be described by equation 2 and
Figure 11. In equation 2, k is the proportionality constant and describes the net growth of
s 4 g of reduction mammoplasty tissue yields 1.5x107 epithelial cells on collagenase digestion (PML).
The average mass of the mammary gland in a non-pregnant post-pubertal female is about 150-200g (Gray's
Anatomy, 38th edition). Therefore, the estimated number of epithelial cells in an adult non-pregnant gland
is about 7.5xl 08, which is about 40% lower than the theoretical estimate derived in Table 3.
-41-
epithelial cells during a fixed time interval and has units of inverse time (time-l).
Separation of the variables in the linear ordinary differential equation expressed in equation
1 yields equation 2, which is the explicit solution.
aNSkN (1)
at ekt (
N = Noekt (2)
Number of cells (N
Nfina
11 16 Time (years)
Figure 11 - Graph depicting exponential growth of epithelial cells in human mammary gland
during puberty
Based on Equation 1, we may obtain values for k by making an exponential fit to
the two data points. We may vary
(1) No in the range of 103-106 holding Nfinal constant at 2x109 or
(2) Nfinal in the range of 108-1011 holding No constant at 105 or
(3) vary both No and Nfinal.
After obtaining a reasonable value for k, we may then use equation 2 to obtain an estimate
of the doubling time of the epithelial cells. Tables 3 and 4 show the various values of k
and doubling times (t2) for different combinations of No and Nfinal.
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Table 4 - Values of k and doubling times (t2) for various values of No holding Nfinal
constant
No Nfinal Ik/cell.yr Doubling time (t2)
103 2x10 9  2.9 0.24 yr = 88 days
104 2x10 9  2.44 0.28 yr = 102 days
105 2x10 9  1.98 0.35 yr = 128 days
106 2x109  1.52 0.46 yr = 168 days
Table 5 - values of k and doubling times (t2) for various values of Nfinal holding No
constant
105 108 1.38 0.50 yr = 183 days
105  109 1.84 0.38 yr = 139 days
105  1010 2.30 0.30 yr = 110 days
105 1011 2.76 0.25 yr = 91 days
Returning to the central hypothesis, we are attempting to determine if there is a
burst of mutations during the growth of a human breast during puberty. It has already
been established by the work of Cha et al., 1994 that such a burst occurs in the rat
mammary gland in the c-H-ras oncogene, beginning around the first estrus. It is therefore
necessary for us to determine if:
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(i) a similar burst occurs in other gene sequences in the pubertal rat mammary gland
(ii)a similar burst occurs in humans in the c-H-ras oncogene
(iii) a similar burst occurs in other gene sequences in the pubertal human mammary gland
In the event that the burst occurs, we must determine
(i) is the burst limited to a specific base change, for example G->A
(ii) determine when it occurs and
(iii) determine the distribution of mutants and the average size of the clusters.
Let's consider the case in which the total number of epithelial cells is less than 107
cells, as is the case for the first net 7 doublings of the pubertal breast (105-107). In the
case in which N = 105 cells, the expected number of mutant cells at the time of doubling of
N would be 10-2, using a mutation rate of 10- 7/cell.generation. Since we cannot speak of
0.01 or 0.1 mutants arising from a population of 105 or 106 cells at the time of doubling,
this is not a good physical representation of the process as the generation of spontaneous
mutants can be considered to be a binomial event, that is, a mutant is generated or it isn't.
Therefore, when N<107 cells, we must think of the probability of finding a cluster of a
specific size from a sample of women rather than thinking of the expected number of
individual mutants which are generated at the time of doubling. Table 6 summarizes the
expected size of a single mutant cluster and the probability of finding a cluster of a specific
size in a sample of women, as a function of the number of epithelial cells in a growing
mammary gland. We must also consider the fact that even at N> 107 cells, there is still a
possibility of not observing any mutants, the probability of which can be determined using
the Poisson distribution.6 Table 5 show the probabilities of not observing a single mutant
6 The Poisson distribution can be described by the equation
P(n)= Xne-l/n! where P(n) is the probability of observing n events and X is the expected number of
events.
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cell and the expected number of independent mutants generated
function of the changing values of N in the developing gland.
necessary to model the total expected number of mutants and
distribution and average colony size.
at each doubling as a
Therefore, it will be
to the determine their
Table 6 - Probability of not observing a single mutant as a function of the number of
epithelial cells in the developing gland (N)
Number of cells at risk (N) Expected number of P(observing no mutants)
independent mutants
1.625x10 5  (0.01625) 0.98
3.25x10 5  (0.0325) 0.97
6.25x105 (0.0625) 0.94
1.25x10 6  (0.125) 0.88
2.5x10 6  (0.25) 0.78
5x10 6  (0.5) 0.61
107 1 0.37
2x10 7  2 0.14
4x10 7  4 1.8x10 -2
8x10 7  8 3.35x10 -4
1.6x10 8  16 1.1x10-7
3.2x10 8  32 1.2x10 -14
6.4x108  64 1.6x10-28
1.28x10 9 128 2.6x10-56
P(o)=e-1 = 1/e = 0.367 as X = 1
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Table 7 - Expected size of mutant cluster and probability of observing a cluster of such a
size in a cross-section of women as a function of the number of cells present in the breast
at the time at which the mutation is obtained
Number of cells at 7Expected size of8 Mutant fraction Probability of
risk (N) single mutant per sector if single observing cluster
cluster in mature cluster of appropriate size
breast
1.625x10 5  214 = 16,384 4x10 -5  2/100 women
3.25x10 5  213 = 8,192 2x10 -5  3/100 women
6.25x10 5  212 = 4,096 1x10-5  6/100 women
1.25x10 6  211 - 2,048 5.1x10 -6  1/10 women
2.5x10 6  210 = 1,024 2.55x10 -6  2-3/10 women
5x10 6  29 = 512 1.3x10 -6  5/10 women
107 28 = 256 6.5xl0 -7 (ND) every woman
2x10 7  27 = 128 3.3x10 - 7 (ND) every woman
4x10 7  26 = 64 1.65x10 -7 (ND) every woman
8x10 7  25 = 32 8.3x10- 8 (ND) every woman
1.6xl 08  24 = 16 4.2x10 -8 (ND) every woman
3.2x10 8 23 = 8 2.1x10 -8 (ND) every woman
7Assume that each single mutant generated at the time of doubling of the breast may give rise to a single
mutant cluster or colony
8 This assumes that the mutant cells do not possess any proliferative advantage over normal cells and both
grow at the same rate.
Each sector will contain 4x 108 epithelial cells (2x109/5 sectors)
After the gland reaches 107 cells, it is expected that there will be more than 1 positive sector per breast
(>107 cells) and more than one mutant cluster per sector (>5x 107 cells). However, the mutant fraction will
not be expected to increase significantly to the point at which the expected mutant fraction increases over
-~6x10-7.
ND means not detectable using the current limits of MAMA.
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This work is based on the detection of mutants in the human pubertal breast. It is
therefore imperative that we consider the different mechanisms forcing the generation of
mutants in the whole mammary gland. In the growing breast, there are two sources of
mutants. The first source is the spontaneous generation of mutants from normal cells
which is driven by the parameter r, which is the spontaneous mutation rate in equation 3.
The second source of mutants is the growth of mutant cells which were generated
spontaneously during previous cell divisions, which will be referred to as preexisting
mutants hereafter. The parameter p in equation 3 is similar to the parameter k for normal
cells and describes the net growth rate for the mutant cells. Again, the effect of this
component is exponential as in the case of normal cells, the rate of growth of the mutant
cells is dependent on the number of existing mutant cells. For predictive purposes, we will
assume that p = k. However, in reality, p may be different from k because the net
turnover rates of mutant epithelial cells may be significantly different from that of normal
cells. In addition, perhaps only a select fraction of the mutant cell population may
actually be undergoing division.
If we attempt to model the total number of mutants as a function of the number of
epithelial cells N in the developing mammary gland, we will arrive at an equation such that
AM = rNAt + pMAt (3)
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6.4x10 8  22 = 4 1.05x10 -8 (ND) every woman
1.28x10 9  2 5.3x10 -9 (ND) every woman
2.56x10 9 1 2.6x10 -9 (ND) every woman
where AM is the change in the number of mutants and At is the change in time. For an
infinitely small At, equation 3 approaches the partial differential equation and becomes
equation 4, where rN is the contribution from the spontaneous generation of mutants and
pM is the contribution from the growth of pre-existing mutants. The premise is that
every mutant cell which arises in the growth of an organ is capable of giving rise to an
independent colony of mutant cells, driven by the component pM.
BMS= rN + pM (4)
at
When the linear differential equation expressed in equation 8 is solved using
integrating factors, the following solutions are obtained. Equation 5 is the solution when p
is different from k. When k > p, ekt - ePt > 0, k-p > 0, and M > 0 growing as ekt. When
p < k, ekt - ept < 0, k-p < 0, and M > 0 growing as ePt. When p = k, the solution
becomes equation 6 because in this case, equation 5 becomes an indeterminant (0/0). The
ratio of p to k determines the total number of mutants such that when p > k, M/N grows
exponentially, when p = k, M/N grows proportionally to time and when p < k, M/N
decays exponentially. The ratio of p to r determines the size distribution of the clusters,
such that when p >> r and p << r, the situations depicted in Figures 12 and 13 result. The
solutions to Equation 4 will allow us to determine the actual value after the number of
mutants is determined from the tissue samples.
M = PNo [ektePt] (5)k-p
M = pNotekt (6)
The first specific condition which we will consider is the case where p << r, that is
the effect of the spontaneous generation of mutants far outweighs the effect of the net
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growth of pre-existing mutants. The effect of p would be to give rise to smaller colonies,
while the effect of r would be the initiation of a large number of independent mutants. The
net effect of this condition would be predicted to be a large number of colonies of smaller
average size. The expected distribution in the mature breast is depicted in Figures 12 and
13.
The second condition which we will consider is the case where p >> r, that is the
effect of the net growth of pre-existing mutants far outweighs the effect of the
spontaneous generation of mutants. The lower value of r would implicate the initiation of
a smaller number of mutant cells capable of giving rise to independent colonies. However,
the value of p would mean that each of these single independent colonies would on average
contain a greater number of mutant cells. The expected distribution in the mature breast is
depicted in Figures 12 and 13. In the case in which p = r, an intermediate situation would
be expected. Figure 11 is a plot of the expected number of colonies versus the expected
number of mutants per colony for the cases p << r and p >> r. In any of the specific
situations described, it is clear that mutants which arise soon before the mammary gland
attains its final N will not have the chance to show themselves as a detectable mutant
colony (see Table 6).
-49-
# of colonies
# mutants/colony
Figure 11- Expected distribution of number of mutant colonies versus the number of
mutants per colony
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p>>r
Driving component is
the growth of pre-existing
mutants
Figure 12
Smaller number of
mutant colonies of
larger size
p<<r
Driving component
is the spontaneous
generation of mutants
Figure 13
Larger number of
mutant colonies of
smaller size
In order to detect these mutant colonies, a minimum mutant fraction of 10-6 - 10 -5
is required. This means that in the mature breast of approximately 2x10 9 epithelial cells
which is divided into 5 equally sized sectors containing approximately 4x10 8 cells, there
must be at least 1 colony containing a minimum of 400 to 4000 mutant cells (see Table 6).
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3. MATERIALS AND METHODS
3.1 Isolating Mammary Epithelial Cells from a Reduction Mammoplasty Sample
One of the major challenges of this work is to obtain a purified fraction of the
epithelial cells lining the ducts. These are the cells which are at risk of getting mutations
and giving rise to carcinomas. The approach which has been used is an adaptation of the
method outlined by Freshney, (1992). The sterile 9surgical discard tissue which was
obtained from reduction mammoplasties was first cut into sections of predetermined
masses so that we may obtain sufficient numbers of epithelial cells for molecular analysis.
The "whitish" areas of the tissue were excised from the remainder of the tissue, which
according to Freshney, (1992) are the regions which contain the ducts. Each tissue section
had an average mass of 106 g. The tissue was then minced using a razor blade and then
placed into a 50 ml centrifuge tube containing approximately 30 ml of tissue processing
media, 10 ml of 5X enzyme solution and 5 ml of fetal bovine serum (FBS). The tissue
processing media contains Ham's F12 nutrient mixture supplemented with insulin (10
gg/ml), penicillin (100 U/ml), streptomycin (100 pg/ml), polymixin B (50 U/ml) and
Fungizone (5 gLg/ml). The enzyme solution consists of collagenase type IV (1,500 U/ml)
dissolved in an appropriate amount of tissue processing media, filtered sequentially
through 0.8 gm, 0.45 gtm, and 0.20 gm Nalgene filters and hyaluronidase (100 U/ml)
dissolved in an appropriate amount of tissue processing media and filtered through a 0.20
9 The tissue used in this work has been kindly provided by Dr. Samuel Singer of the Brigham and Women's
Hospital in Boston.
[0) A 4g mass of breast tissue obtained from a reduction mammoplasty (Dr. Sam Singer) yielded an average of
3x107 cells (samples HBDRAI (PML) and HBDRIE (PML)). Assuming that this cell fraction contains
about equal proportions of epithelial cells and fibroblasts, then there are 1.5x107 epithelial cells in this
sample. Assuming that on average 1 g of tissue contains about 108 cells, then 4 g of tissue should contain
4x10 8 cells. Therefore in the 4 g sample, the epithelial cells constituted approximately 3.75% of the whole
tissue sample.
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gtm Nalgene filter. Equal volumes of the sterile collagenase solution and the hyaluronidase
solution were mixed together to give the 5X solution.
The second step in the overall process is the overnight digestion of the tissue
sections with the 5X enzyme solution, the tissue processing media and the fetal bovine
serum at 370C in a shaker water bath. Collagenase digestion yields primarily fibroblasts
and epithelial cells. The centrifuge tubes were then spun at 800g for 10 minutes and the
overlying fat layer and the media layer were both removed. The remaining pellet was then
resuspended in 5 ml of mammary epithelial growth medium (MEGM - Clonetics, CA)
using a 5 ml pipetteman. One drop was placed on a microscope slide to determine the
degree of completion of digestion. If microscope examination revealed that there were still
epithelial cells attached to the surrounding stroma, then digestion with the mix of 5X
enzyme solution, tissue processing media and FBS was carried out again for another 3
hours. This process is repeated until microscope examination revealed that digestion was
complete. After digestion was complete, the cell pellet was resuspended in 4 ml of
MEGM and 1 ml was counted using a Coulter counter and the remaining 3 ml were split
between three 25 ml T flasks. 5 ml of MEGM was added to each flask.
The next step is primarily for separating the fibroblasts from the epithelial cells
and takes advantage of the fact that fibroblasts attach more readily to the surface of a
plastic tissue culture dish. The fibroblasts attach within 1-2 hours of seeding the culture,
whereas epithelial cells will attach several hours later. Two hours after the first set of
cultures were seeded, the media from each of the flasks was transferred to a new flask.
Again, two hours after the second set of cultures were seeded, the media from each of the
flasks was transferred to another set of new flasks. New media was added to both the first
and second set of flasks. The three sets of cultures were grown for several days in an
effort to determine the types of cells which attached and survived.
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Indeed, after 5 days of growth in an incubator kept at 370 C, two of the three flasks
from the third set contained only epithelial cells and the third flask contained mostly
epithelial cells with about 20% clones of fibroblasts. The first and second sets of flasks all
contained fibroblasts. These results could mean that the differential attachment procedure
was successful in separating the epithelial cells and the fibroblasts at the end. On the other
hand, it could be that there were actually epithelial cells which had attached to the surface
of the flasks in the first and second sets of flasks. However, the rapidly growing sturdy
fibroblasts in culture overgrew the epithelial cells. In any case, the predominance of
epithelial cells in the third set of flasks indicate that the separation was successful, and if
indeed there were epithelial cells which were lost in the first and second set of flasks, the
efficiency of the procedure would have to be improved. Figure 14 is a picture of the
attached epithelial cells in culture. The cells were typed based on their morphologies.
However, definitive typing of the cells should be done immunohistochemically using
antibodies against cytokeratins, which appear on the surface of epithelial cells only.
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3.2 Histology of the Reduction Mammoplasty Sample
A single 4 g piece of tissue from the same reduction mammoplasty sample was
fixed in 40 ml of neutral buffered formalin (NBF) for 10 days at 4 OC. The sample was
then paraffin embedded and sections were made which were stained with the dyes,
hematoxylin and eosin (H&E). Figure 15 is a photo of the slide of a cross section of the
ducts surrounded primarily by adipocytes and some loose connective tissue.
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3.3 Alternative Approaches for Separating Fibroblasts and Mammary Epithelial
Cells
Other possibilities for the separation of the population of fibroblasts and epithelial
cells which are derived from the collagenase digestion of the surgical samples include
* separation of the cells using a medium (Percoll) composed of colloidal silica coated with
polyvinylpyrrolidone (PVP) for density gradient centrifugation of the cells (Pharmacia
Biotech)
* use of magnetic beads (Dynal) conjugated to antibodies to cytokeratin 19 on the surface
of epithelial cells or
* use of fluorescent antibodies to cytokeratin 19 on the surface of the epithelial cells and
separation of the cell types using a fluorescence activated cell sorter (FACS).
3.4 Cell Culture for Obtaining Positive and Negative Controls
The positive controls which were to be used for MAMA in reconstruction
experiments and the actual samples were obtained from cell lines derived from tumors.
The GGC->GTC (glycine->valine) mutant which was used to assay the codon 12 c-H-ras
mutation was derived from a human bladder carcinoma cell line, T24 (Capon et al., 1983).
The GTC->TTC (valine->phenylalanine) mutant which was used to assay the exon 5 -
codon 157 mutation was derived from the H2087 cell line, derived from a small-cell lung
carcinoma (SCLC) and was a generous gift from Dr. Herb Oie (National Cancer Institute).
TK6 (human B lymphoblastoid cell line) DNA was used as the negative control and was a
gift from Ms. Jackie Goodluck-Griffith (MIT Center for Environmental Health Sciences).
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H2087 cells were grown in RPMI 1640 media (Gibco-BRL) supplemented with
10% horse serum (Gibco-BRL). They were grown in 75 ml plastic T-flasks. TK6 cells
were grown in suspension using RPMI 1640 media (Gibco-BRL) supplemented with 10%
bovine horse serum (Gibco-BRL). T24 cells were grown in 75 ml plastic T-flasks using
RPMI 1640 media supplemented with 10% bovine calf serum (BCS, Gibco-BRL). Cell
stocks were counted using a Coulter counter. Cell stocks which needed to be frozen were
first centrifuged at 1000g for about 15 minutes in either a 10 ml or 50 ml centrifuge tube
and were resuspended in fresh media supplemented with 10% DMSO.
3.5 Genomic DNA Extraction
3.5.1 Extraction Protocol
The extraction of genomic DNA (gDNA) from cell lines which are used as both
positive and negative controls is done using the protocol described by Khrapko et al.
(Manuscript in preparation). The protocol may also be used for the extraction of DNA
from a purified fraction of mammary epithelial cells or from a tissue section, in the case of
an organ which is composed mainly of a single cell type.
The volumes quoted in the following description have been optimized for the
extraction of genomic DNA from approximately 5x10 6 cells of cells in suspension or from
a 20 mg tissue section. The cells are resuspended as evenly and as gently as possible in
450 jgL of standard TE buffer, pH 8.0 (50 mM Tris/HC1, 10 mM EDTA, pH 8.0). 25 tgL
of proteinase K (20 mg/ml) is added to the suspension, followed by 25 RLL of 10% sodium
dodecyl sulfate (SDS) and it is digested for 3 hours at 550 C. This is then followed by the
addition of I gL of 10 mg/ml RNase A and is digested for 45 minutes at 370 C in a shaker
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water bath. The digest is then centrifuged for 15 minutes at 12,000 rpm and the
supernatant (approximately 80-90% of the original volume) is removed. Centrifugation
allows the high molecular weight DNA to stick to the sides at the base of the tube. 20 gL
of 5M NaCI is then added to the remaining suspension. The DNA in the remaining
suspension is then precipitated by the addition of 900 gL of 100% ethanol and increasing
the speed of vortexing. The 100% ethanol is then removed and the DNA spool is washed
by adding 800 gLL of 70% ethanol. A small volume of the 70% ethanol is left in the tube
so that the DNA spool never becomes completely dry. Otherwise, it would be very
difficult to dissolve the DNA. The resulting DNA spool is then transferred to
approximately 500 jgL of a 20X dilution of standard TE buffer , pH 8.0 (2.5 mM
Tris/HCl, 0.5 mM EDTA, pH 8.0).
3.5.2 Determining the yield of DNA after extraction
A rough determination of the yield of DNA is determined by running the final
DNA solution dissolved in a 20X dilution of TE buffer, pH 8.0 in parallel with standards
of 3,10, 30, 100 and 300 ng of high molecular weight herring DNA on an 8% PAGE gel.
The gel is run for 2 hours at 250 V and a comparison of the intensities of the smeared
bands representing the actual samples with the standards allows an estimation of the final
concentration of DNA.
Two more accurate methods of determining the yield of the DNA extraction
procedure include (i) measuring the absorbance of the DNA sample at 260 nm using a uv
spectrophotometer and (ii) coamplifying a specific sequence of a single copy gene such as
the APC gene with a known number of copies of an internal standard.
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Expecting approximately 6 lgg of DNA from 106 cells, I achieved a yield of 120%
for gDNA extraction from T24 cells and 150% from TK6 cells as determined by the
absorbance at 260 nm on the uv spectrophotometer. This indicates that either (i) the
estimate of 6 ag of DNA/10 6 cells is an underestimate, as not all the cells at the time of
freezing may have been strictly diploid (they are diploid but are doubling their DNA),
depending on which phase of the cell cycle the cell is in or (ii) the cell count given by the
Coulter counter is an underestimate as cells may be clumping.
3.5.3 Determining copy number using an internal standard
The number of copies of a specific sequence may be determined if the assumption
is made that there has been no gene amplification. For example, the number of copies of
the p53 tumor suppressor gene and the c-H-ras oncogene from a specific DNA
preparation may be determined using the number of copies of the wildtype APC tumor
suppressor gene as a benchmark. An APC point mutant which runs as separate peak from
the wild type using constant denaturing capillary electrophoresis (CDCE) at a temperature
of 64°C was used. A population of these mutants at a concentration of 105copies/pl was
obtained from Dr. Gengxi Hu. An estimated 1:1 mixture of APC mutant:(TK6/T24/H2087
DNA) was amplified using primers which did not differentially amplify either mutant or
wildtype. The ratio of the wildtype peak area to the mutant peak area multiplied by the
concentration of mutant copies yields the concentration.
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3.6 Mismatch Amplification Mutation Assay (MAMA)
3.6.1 The General Method
The mismatch amplification mutation assay (MAMA) was developed by Dr. Rita
Cha and is a variation of PCR which allows selective amplification of a mutant allele
versus a wildtype allele. This is achieved by the use of a mismatch primer which has a
double mismatch with the wildtype allele and a single mismatch with the mutant allele at
the 3' ultimate or penultimate end (Cha et al., 1992). MAMA has been shown to have a
sensitivity of 10-5 for a specific G->A mutation at the second nucleotide of codon 12 in
the c-H-ras gene. Thus it can detect 30 mutant copies among 3x10 6 copies of the
wildtype.
For each specific mutation which needs to be assayed, a series of mismatch primers
each with a different mismatch needs to be screened using pure mutant DNA as a
template, in order to determine the primers with the best chances for achieving a MAMA
assay with the highest sensitivity. Primers which contain mismatches with T have the
lowest probability of extending the mutant allele in a MAMA assay (Personal
communication, Dr. Rita Cha). Therefore, primers have been designed to incorporate G-G,
A-G, A-A, A-C and C-C mismatches, in order of decreasing extension efficiencies.
After the initial screening of the set of primers, the conditions for each potential
primer must be optimized before the limit of sensitivity of the MAMA assay may be
determined via a reconstruction experiment. A typical 50 RL MAMA reaction is
composed of: approximately 1-5 gLg of genomic DNA (3x10 5 -1.5x10 6 copies), 200 nM of
each primer or 6x10 12 copies of each primer (one of which is fluorescein labeled), 4 mM
MgCl2, 0.15 mM dNTPs or 4.5x10 15 dNTP molecules, 5 Units of Stoffel DNA
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polymerase (Perkin-Elmer Cetus), 0.5 lgL of 100X BSA and IX Stoffel buffer (10 mM
Tris-HCL, 10 mM KC1, pH 8.3). The MgCl2 is provided separately as a 25 mM stock
solution. The Stoffel fragment of Amplitaq DNA polymerase is being used as it lacks an
additional level of proofreading activity over Taq DNA polymerase. It lacks both 5' to 3'
and 3' to 5' exonuclease activities, while Taq polymerase only lacks the 3' to 5'
exonuclease activity. It is a 61 kD, highly thermostable enzyme which lacks the N-
terminal 289 amino acid portion of AmpliTaq. For this reason, the Stoffel fragment of
Amplitaq can be used to discriminate and extend more efficiently, primers which have a
single mismatch with the wildtype and a perfect match with the mutant.
The variables which need to be optimized prior to the reconstruction experiments
are the annealing temperature, the concentration of NaC1, and the concentration of
glycerol". The annealing temperature in general is increased as close as possible to the
lowest melting temperature of the two primers, in order to decrease the amount of non
specific amplification arising from hybridization with random sites in the genome. For a
20 bp primer, the probability of annealing to any site with perfect complementarity in the
genome is (1/4)20. The addition of 25 mM NaCl (final concentration) increases the
specificity of annealing of the primers (unpublished observation, PML). The positively
charged sodium ions tend to act as a sort of "glue" to bind the negatively charged primers
and DNA template.
I It has been shown that 5-10 % vol/vol of glycerol increases the specificity of MAMA (Cha et al., 1992).
However, levels greater than 15% actually inhibit the reaction.
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3.6.2 Sequence of Mismatch Primers and Design
The sequences of the primers used in the MAMA assays for the detection of both
G->T mutations in codon 12 of the c-h-ras gene and in codon 157 of exon 5 are listed
below. There is an A/G mismatch between the mismatch primers and the wildtype
sequence for both mutations.
jrasl2U I
rasl2
ras12U-ms12D 223bp
rasl2U-ras12PM 128bpF51
Irasl2PM rasl2D
Figure 16 Schematic of codon 12 H-ras G->A mutant MAMA primers and product
lengths
rasl2U - 5' GCT GAG CAG GGC CCT CCT TG 3'
rasl2D - 5' AGC TGC TGG CAC CTG GAC GG 3'
rasl2PM - 5' CGC ACT CTT GCC CAC ACC GA 3'
jp53157U I
p53-157U-p53157D 214bp
p53157U-p53157PM 128bp4 -5 I
p53157PM p53157D
Figure 17 Schematic of p53 codon 157 G->T mutant MAMA primers and product
lengths
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p53157U - 5' CTT CCT GCA GTA CTC CCC TG 3'
p53157D - 5' GCC CCA GCT GCT CAC CAT CG 3'
p53157PM - 5' TAG ATG GCC ATG GCG CGG AA 3'
3.7 Optimizing the System - The Story of the Positive Controls
Before the reconstruction experiments can be carried out for determining the
sensitivity of the assay, the system must first be calibrated using a dilution series for the
positive control. Such a system has been tested only for the c-H-ras codon 12 mutation
using T24 DNA as the positive control. High molecular weight herring DNA was used as
the carrier DNA i.e. the DNA without any copies of the mutant h-ras sequence. This is
important so that there will be no background signal generated. Both the herring DNA and
the T24 DNA were subjected to a simultaneous 24 hour restriction digestion using the
enzyme PstI. The completeness of digestion was checked on an 8% PAGE gel.
The carrier DNA is important for keeping the total amount of DNA constant from
dilution to dilution. A series dilution was made, adding the appropriate amount of herring
DNA to each eppendorf tube to pre-coat the walls. At very low dilutions of the positive
control (10-1000 copies/ul), it is possible that the restriction digested DNA sticks to the
side of the walls and are unavailable for amplification, thus artificially rendering the system
non-linear. Restriction digestion of the DNA increases the amplification efficiency by
approximately 20% (unpublished data, PML). The absolute positive control was 106
copies of T24 DNA or approximately 3.3 ug. The absolute negative control was 3.3 ug of
herring DNA. For the series dilutions, the range of initial copy numbers of T24 postive
control was from 105, 104, 103, 100 and 10 copies per 25 ul PCR reaction. 4 units of
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Stoffel polymerase were used per reaction with 4 mM MgC12. The cycling profile was
950 C for 15 seconds, 620 C for 25 seconds and 720 C for 25 seconds. The reactions
containing 106 and 105 copies of T24 DNA were run for 30 cycles, 104 copies for 35
cycles, 103 copies for 40 cycles, 100 copies for 45 cycles and 10 copies for 50 cycles.
This protocol of cycle numbers was used to avoid overamplification of the product and
possible nonlinearity in the amplification results.
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APPENDIX
Al.l History of Rodent Mammary Neoplasia
The use of rodent models has advanced our understanding of the mechanisms of
mammary neoplasia. Guillino and his colleagues began laying the foundation for the field
as far back as 1975 when they treated 50 day old female Buf/N rats with the potent
carcinogen and mutagen, N-nitroso-N-methylurea (NMU) at a dose of 30 mg/kg (Guillino
et al., 1975). They discovered that 90% of the treated rats developed mammary
carcinomas about 60 days after exposure to the carcinogen. About 8 years later, Sukumar
et al. (1983) were able to demonstrate that each of the 9 mammary carcinomas which arose
subsequent to the treatment of 50 day old Buf/N rats with NMU contained a transforming
H-ras allele. The field moved closer to determining whether chemicals cause mammary
tumors by mutating specific cellular targets, in particular, oncogenes with the experimental
results of Zarbl et al., (1985). They demonstrated that when 50 day old female Sprague-
Dawley, Buffalo and inbred Fischer 344 (F344) rats were treated with a carcinogenic dose
of either NMU (30 mg/kg) or dimethylbenz(a)anthracene (DMBA), approximately 75% of
the mammary tumors developed in the rats treated with NMU carried a G->A transition
mutation at the second nucleotide of codon 12 in the c-H-ras-1 gene. The DMBA induced
mammary tumors on the other hand carried specific A->T transversion mutations in codon
61 of the c-H-ras-1 gene. They reasoned that since the particular G->A mutations were
present in the NMU-induced tumors only and not in the DMBA-induced tumors, that
NMU induced the mutations in the c-H-ras gene and perhaps contributed to the initiation
of carcinogenesis. This development set the stage for the ideas that (1) each chemical had a
specific cellular target and perhaps a hallmark or preferred base change (GC->AT for
NMU and AT->TA for DMBA) and that (2) the genetic change was responsible for the
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development of the mammary tumor (first evidence of a link between mutagenesis and
carcinogenesis).
A1.2 Timing of Initiation
After it was established that NMU induced tumors reproducibly carried a G->A
mutation at codon 12 of the c-H-ras gene, may researcher began to focus on determining
the exact timing of this genetic insult. Lu and Archer, (1992) were trying to understand the
molecular basis of the differential susceptibilities of the Buf/N and the Copenhagen rat to
mammary carcinogens. Earlier experiments which they had performed showed that
kinetics of formation and repair of 06-methylguanine in the mammary tissue of both
strains of rats were identical. In addition, the extent of methylation of a restriction
fragment containing exons 1-4 of the c-H-ras gene by NMU and the level of H-ras
expression in mammary tissue was not different for the two strains. They therefore
decided to measure the frequency of activated codon 12 H-ras alleles in the mammary
epithelium of both strains of rats following exposure to 30 mg/kg or 50 mg/kg or NMU.
They thought that perhaps the differential susceptibility between the two rats lay in either
the timing of initiation or a lack of initiation in the Copenhagen rat.
Interestingly, 30 days after treatment with NMU, a few of the glands tested in the
Buf/N rats had mutant fractions of about 10-5. At 60 days post-treatment, several of the
glands had mutant fractions between 10-4 and 10-3, an increase of about 10-100 fold. This
increase in the number of mutant cells is in agreement with the normal proliferation of the
mammary epithelium during puberty. In contrast, none of the 40 glands tested from the
control rats contained the mutations (mutant fraction > 10-5). In the case of the
Copenhagen rat, 30 days after treatment, there were four positive glands containing mutant
fractions of 10-4 to 10-5 and 15 glands with mutant fractions of 10-5 . Sixty days after
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treatment, 19 of the glands tested were positive with mutant fractions of 10-5. None of the
40 glands tested in the control Copenhagen rats were positive (had mutant fractions > 10-
5). The authors concluded that since both the mammary epithelium from both the Buf/N
and Copenhagen rats contained ras positive mutants, then the difference in susceptibility
to mammary carcinoma induction was not a result of lack of initiation of the ras alleles.
They hypothesized that perhaps it is due to the expression of a dominant autosomal
suppressor gene in the mammary parenchyma of the Copenhagen rats, which prevents the
proliferation of the activated ras epithelial cells into tumors.
There are two main problems with their interpretation which does not allow me to
fully accept their conclusions. In the first place, the claimed sensitivity of their assay is
10-5. However, in the molecular analyses, the authors used 1 ug of DNA which is
equivalent to 3x10 5 copies of the ras allele. This means that at a mutant fraction of 10 -5 ,
there should theoretically be 3 copies of the ras allele. However, according to the
statistical variation as predicted by the Poisson distribution, the actual number of copies
can range from 0 to 7 copies of the allele per sample. Therefore, it is possible that there
are positive glands, which may contain activated ras alleles at mutant fractions of 10 -5 or
lower and which cannot be detected by the assay. Such glands have effectively been
scored as zero by the authors. Secondly, molecular analysis was not performed on all of
the 12 glands in the rats. Therefore, it is possible that there are positive glands which have
not been detected both in the treated animals and in the control animals. Such uncertainties
motivate me to entertain the possibilities that the mammary epithelium of both strains of
rats (both treated and control) might contain activated ras alleles.
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A1.3 NMU Background
NMU is most commonly used for the laboratory synthesis of diazomethane. It
has been used extensively in cancer research as a model compound to determine the
molecular mechanisms underlying exogenous and endogenous nitrosamine carcinogenesis.
It is a cytotoxic, mutagenic, teratogenic and carcinogenic compound. It has been tested in
numerous animal species thus far and all were susceptible to NMU induced carcinogenesis.
It is a potential human carcinogen based on its mutagenicity and animal carcinogenicity.
It is highly reactive and spontaneously decomposes quite rapidly at neutral or
basic pH. It has an estimated half life of 30 minutes in vivo. NMU is readily sequestered
within cells and for this reason, rapidly disappears from the blood stream of a rat and is
uniformly distributed among the different organs of an animal within hours of i.v.
administration. NMU decomposes to form the highly reactive metabolites,
methyldiazohydroxide and isocyanate. The first metabolite is a methylating agent while
the second is a carbamoylating agent. Methyl diazohydroxide reacts primarily with
proteins, DNA and RNA inside a cell, while the cyanate ion reacts primarily with
proteins. NMU reacts with both eukaryotic and prokaryotic DNA to form many
promutagenic alkylated adducts. Figure 18 describes the spontaneous decomposition of
NMU at neutral or basic pH
CH3-N20-CO-NH2 ---------------- > CH 3N=NOH + HNCO
NMU methyl diazohydroxide isocyanate
Figure 18 - Spontaneous decomposition products of NMU
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A1.4 Mutational Specificity of NMU in bacterial and mammalian cells
Further evidence for the hypothesis linking mutagenesis and carcinogenesis came
from experiments detailing the mutational specificity of NMU in bacterial and mammalian
cells and other rodent carcinogenicity models. Other chemicals which were used in the
rodent assays included the polycyclic hydrocarbon DMBA and N-methyl-N'nitro-N-
nitrosoguanidine (MNNG).
Richardson and colleagues (Richardson et al., 1987) characterized the DNA base
changes and measured the levels of DNA alkylation following in vivo exposure of E.coli to
NMU and N-ethyl-N-nitrosourea (ENU). They subjected E.coli carrying the xanthine
phosphoribosyl transferase gene (gpt) as the genetic target on the plasmid pSV2gpt with 7
mM MNU or 35 mM ENU. They then compared the resulting mutational spectra
(frequency of base changes, types of base changes and the sequence specificity of base
changes) with the concentration of alkylation adducts (06-alkyl guanine and 04 alkyl
thymidine) in the genomic DNA after exposure. Numerous in vitro misincorporation
studies, in vivo site directed mutagenesis studies and in vivo studies comparing the specific
adducts formed after treatment with alkylating agents and the resulting mutation
frequencies have suggested that the principal promutagenic lesions are 04 alkylthmidine
and 06-alkylguanine. For NMU induced mutagenesis, it was hypothesized that the 06-
methyl guanine adducts were the most important lesions. In order to determine if 06-
methylguanine lesions were responsible for the mutations induced in intact cells, 06-
methylguanine adducts were incorporated into a specific site of a viral genome and allowed
to replicate in vivo. In vivo replication in bacterial systems (Loechler et al., 1984) and in
mammalian systems (Mitra et al., 1989) resulted in GC->AT transition mutations. Singer
et al., (1986) and Safihill et al., (1985) have shown that an alkylated guanine causes
-71-
mispairing with a thymine during DNA replication in vitro, thereby fixing a G->A
mutation.
Richardson et al., (1987) found that 100% of the NMU mutations were GC->AT
transitions, in contrast to 73% of the ENU mutations. 21% of the ENU mutations were
AT->GC transitions, 3% were GC->CG transversions and 3% AT->CG transversions.
The profile was very different for the spontaneous mutants which comprised 41%
insertions, 47% deletions, 6% GC->AT transitions and 6% GC->TA transversions.
NMU demonstrated a positional specificity with 82% of the GC->AT transitions
occurring at a middle guanine flanked by another guanine at the 5' position and either an A
or a T at the 3' position. 71% of the ENU GC->AT transitions showed this specificity.
The ratio of 04-alkylthmidine to 06-alkylguanine was 0.014 for NMU and 0.28
for ENU, suggesting that perhaps the specific ratio of promutagenic adducts may be
responsible somewhat for the different mutational spectra observed. The mutation
frequencies for both NMU and ENU were however remarkably similar, with each having
an average of 4x10 -5. The spontaneous mutation frequency was 13% that of NMU and
ENU and was 0.55x10 -5 . The similarity in mutation frequencies despite beginning with 5
fold less NMU and a combined alkylation due to NMU being 2.8 fold higher than that due
to ENU suggests (1) that NMU is about 14 fold more reactive with the DNA at the
specific site and that (2) the ethylated adducts are more efficient at fixing the promutagenic
lesions into mutations, maybe due to enhanced mispairing or reduced or less efficient
repair.
In the realm of NMU mutagenesis in human cells, DuBridge et al., (1987) used
stable autonomously replicating Epstein-Barr virus (EBV) vectors carrying the bacterial
lacI gene as the mutational target and established them in late passage 293 human
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embryonic kidney cells. The vectors were later returned to E.coli for colony scoring for
mutation detection and analysis. An NMU stock solution of concentration 10 mg/ml was
added to the growth medium of the kidney cells at 30-40% confluence.
97% of all of the nonsense mutations and 97% of all the missense mutations were
GC->AT transitions, implying that NMU has quite an overwhelming preference for GC-
>AT base changes. Inspection of the local sequence surrounding the mutated guanines in
the missense mutations reveal that 74% of them have a 5' guanine, indicating a sequence or
positional specificity. In fact, 48% of the mutated guanines occur within a run of 3
guanines. The 3' base specificity of an A or T observed by Richarson et al., (1987) was
not observed by Dubridge et al., (1987). Theses studies provided support for the notion
that NMU has a preferred base change and positional specificity and may indeed by
responsible for the G->A mutations observed in the mammary carcinomas of rats treated
with NMU.
A1.5 Further evidence for the mutational specificity of NMUfrom rodent models
The conclusions of Zarbl et al. were further corroborated by a number of rodent
experiments in which a carcinogenic chemical other than NMU was used to induce
carcinogenesis. Quintanilla et al. (1986) also found AT->TA transversions at codon 61 in
over 90% of skin tumors induced in mice by treatment with DMBA. The molecular
analysis was performed using an XbaI restriction enzyme polymorphism (the mutant was
XbaI digestible). They also found that in a total of 12 tumors obtained from NIH mice
treated with MNNG (6 papillomas and 6 carcinomas), none had the XbaI polymorphism,
indicating that the two chemicals induced different mutations. Further support for the
positional specificity of NMU was also obtained from the work of You et al. (1989) who
compared the nature of proto-oncogene activation between spontaneously and NMU
-73-
induced lung tumors in strain A mice. They found that in the spontaneously derived
tumors, 60% of the point mutations occurred at codon 12 of the Ki-ras gene while 30%
occurred at codon 61 of same gene. This contrasts with the NMU induced tumors in
which 100% of the mutations occurred at the middle guanine of codon 12 in the Ki-ras
gene and were GC->AT (GGT->GAT) transitions. This further shows that while each
chemical has its preferred base change, it has a different genetic target and target organ,
which is dependent on the species treated.
Al.6 Formation of 06-methylguanine in DNA and its repair by 06-methylguanine
methyltransferase (MGMT)
In addressing the mechanism of induction of mammary neoplasia in rats after
treatment with NMU, it is imperative that a discussion of kinetics of formation and
removal of the DNA lesion, 06-methylguanine and its removal by the repair enzyme 06-
methylguanine methyltransferase (MGMT) be included. 06-methylguanine has been
shown to lead to G->A mutations and to be the primary promutagenic lesion incurred in
DNA after treatment with any member of the class of alkylating agents. There have been
attempts to correlate the level of this specific adduct after treatment with an alkylating
agent with the frequency of appearance of phenotypic expressions of transformation, such
as tumors or preneoplastic lesions, using animal models. Qin et al. (1991) quantified the
levels of DNA adducts formed in vivo in rat colon mucosa after a single treatment with
varying concentrations of NMU. The phenotypic end point for their work was the
appearance of aberrant crypt foci (ACF), some 4-16 weeks after treatment. They
determined that the formation of adducts was dose-dependent, ranging from an average of
5-308 fmol/ug of DNA for treatment by NMU concentrations ranging from 1.5mM to 75
mM. The formation of ACF was also dose-dependent, increasing up until the 8th week.
In contrast, there were no observable lesions in the control rats. Interestingly, the authors
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in a previous experiment found specific G->A transition mutations at the 2nd nucleotide
of codon 12 of the Ki-ras gene in the cells of the ACF.
Evidence from a number of animal and cell culture experiments show that repair of
the 06-alkyl guanine adducts (independent of their origin) protects cells against malignant
conversion. The O6-alkylguanine adduct has been shown to be repaired by the enzyme,
06-methyl(alkyl)guanine-DNA-methyltransferase (O6-MGMT). It is known that NMU
induces tumors preferentially in tissues with low 06-MGMT activities, either because of
low rates of synthesis of the protein or production of less efficient molecules. 06-
MGMT repairs alkylated bases by removing the alkyl group and adding it to a cysteine
residue within the protein. This reaction inactivates the protein and is referred to as
"suicide inactivation". For this reason, the reaction for the resolution of alkylated bases is
stoichiometric. Qin and his colleagues had previously proven that increasing the levels of
MGMT activity decreased the susceptibility of animals to tumor induction by N-nitroso
compounds. They determined this by the use of transgenic mice in which the E.coli
MGMT gene (ada) attached to the Chinese hamster metallothionein I gene promoter had
been introduced.
There has also been some synergy between two separate aspects of research on
alkylating agents. On the one hand, there are the experiments which have quantified the
levels of DNA adducts and MGMT in normal cells, in order to determine the levels of
alkylating agents and the threshold values of alkylated adducts necessary for the malignant
transformation of normal cells. On the other hand, there is another set of experiments
which attempt to quantify the levels of MGMT in tumor tissue and non-target tissue, in
order to determine their susceptibilities to a class of alkylating agents which are used as
chemotherapeutic agents (methylating and chloroethylating nitrosoureas). Chemicals such
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as chloroethylnitrosourea (CNU) and 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) are
included in this class.
Maze and Sampson, (1996) recently published some work in which they found
that increasing the levels of MGMT in bone marrow stem cells rescues mice from the
cytotoxic effects of BCNU. BCNU is a common chemotherapeutic agent but its success is
compromised by the accompanying severe bone marrow toxicity which results in the
cumulative depletion of all hematopoietic lineages (pancytopenia). It is used in high doses
for the elimination of lymphomas, breast tumors, lung tumors, gastrointestinal tumors and
childhood and adult glial tumors. The overall conceptual approach of eliminating the "bad
guys" and leaving the innocent "bystanders" untouched is of practical application in the
field of human chemotherapy. It is hypothesized that the cytotoxic effects of BCNU on
bone marrow cells is mediated by the inefficient repair of the 06-chloroethyl-guanine
DNA adduct which subsequently rearranges to form interstrand crosslinks, severely
inhibiting DNA replication.
The levels of MGMT expressed are tissue and cell-dependent. It has been found
that bone marrow cells, epithelial cells lining the colonic mucosa and brain cells all express
relatively low levels of MGMT, leading to inefficient and reduced repair of alkylating
lesions in these tissues. Maze and Sampson introduced a retroviral vector expressing the
human MGMT gene under the control of the phosphoglycerate kinase promoter (PGK-
MGMT) into the accessible mouse bone marrow stem cells. Bone marrow cells harvested
from the transplanted animals displayed extensive resistance to BCNU cytotoxicity in
vitro. In addition, the mice also showed a decreased mortality due to pancytopenia
subsequent to BCNU treatment.
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Other groups have also measured the level of MGMT in various human normal and
tumor tissues. In particular, Musarrat et al. (1995) measured the levels of 06-MGMT in
6 normal breast samples (reduction mammoplasty), 17 benign breast samples and 18
breast tumor samples. The average levels in the three groups of samples were 0.221,
0.224, and 0.502 pmol/mg protein respectively. The levels obtained by another group of
researchers (Grafstrom et al., 1984) for other tissues were 0.261 pmol/mg for the human
normal colon, 0.217 pmol/mg for the normal human esophagus, 0.122 pmol/mg for the
normal human lung, 0.076 pmol/mg for the normal human brain and 0.873 pmol/mg for the
normal human liver.
Preuss et al. (1995) have also measured the levels of 06-MGMT in breast and
brain tumors, primarily in an effort to determine the overall resistance of the tumor cells to
the cytotoxic activities of chemotherapeutic alkylating agents. They assayed 68 breast
carcinomas (ductal invasive carcinoma, lobular invasive carcinoma, medullary invasive
carcinoma and recurrencies) and 38 brain tumors (pikocytic astrocytoma, low grade
astrocytoma, anaplastic astrocytoma and glioblastoma multiformae) and found that the
mean level in the breast tumors was 321 fmol/mg protein, which is about 40% lower than
the mean level determined by Musarrat et al., (1995) (ranging from below the level of
detection to 863 fmol/mg protein) In brain tumors, it was 6-fold lower at 55 fmol/mg
protein (ranging from below the level of detection to 238 fmol/mg protein).
There appears to be much interindividual variation in the levels of the MGMT
enzyme, perhaps suggesting a subgroup of people who are more susceptible to alkylation
induced carcinogenesis. It is unknown whether the interindividual variation reflects the
natural genetic diversity of the population, inducibility of the repair enzymes perhaps in
individuals who are exposed to higher levels of environmental carcinogens or just the
natural mosaic cellular composition of the tissues. Fritz et al. (1991), Laval et al. (1991)
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and Chan et al. (1992) have all shown that MGMT gene expression is inducible since they
observed that the MGMT mRNA and protein levels increased upon exposure to genotoxic
stress in rat liver cells. The mechanism of MGMT inducible gene expression is unclear. It
could be a lack of transcription factors activating the promoter, changes in the methylation
pattern of the gene or chromosome loss or simple dilution of the protein due to extensive
cell division. It would be interesting to determine if this interindividual variation is
reflected in any disease pattern. For example, maybe the subset of the women who get
early breast cancer have naturally lower levels of MGMT, making them more susceptible
to both endogenous and exogenous DNA alkylation damage.
MGMT definitely displays tissue, cell and species specific patterns of expression.
It is expressed in nearly all non-established human fibroblast cell lines but is lacking in
about 20% of human tumor and various immortalized cell lines (Mex-). Day et al., (1980)
have also shown that it can be lost in the course of cell transformation by tumor virus
infection. It would definitely be interesting to determine if a lack of expression of MGMT
or a lower than normal level of expression plays a role in human mammary carcinogenesis.
Such issues as (1) do mex- cells have a selective growth advantage either by some direct or
indirect mechanism and (2) are the mex- cells more vulnerable to transformation need to be
adressed.
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